{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:58:02Z","timestamp":1777874282699,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Bundesinstitut f\u00fcr Risikobewertung (BfR)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Einleitung<\/jats:title>\n                    <jats:p>In der Nutztierhaltung werden Antibiotika oft zur Behandlung von Tiergruppen eingesetzt, z.\u202fB. bei Gefl\u00fcgel. Mit der 16.\u00a0Novelle des Arzneimittelgesetzes wurde 2014 in Deutschland das Antibiotikaminimierungskonzept eingef\u00fchrt. In der Folge reduzierte sich die Therapieh\u00e4ufigkeit in vielen Tierpopulationen. Ziel dieser Studie ist es, die Entwicklung des Antibiotikaeinsatzes und der Resistenz in den Populationen von Mastputen und -h\u00fchnern und die Auswirkungen auf die Resistenzsituation in der Humanmedizin darzustellen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methoden<\/jats:title>\n                    <jats:p>\n                      Die Therapieh\u00e4ufigkeiten bei Mastputen und -h\u00fchnern wurden f\u00fcr 2014\u20132024 mit den aus dem Zoonosen-Monitoring stammenden Resistenzraten von\n                      <jats:italic>Escherichia (E.)\u00a0coli, Campylobacter (C.)\u00a0coli<\/jats:italic>\n                      und\n                      <jats:italic>C.\u00a0jejuni<\/jats:italic>\n                      gegen\u00fcber Antibiotika verglichen und anhand der Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA)-Arbeiten in Bezug zur Resistenzsituation beim Menschen gesetzt.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>\n                      Die Therapieh\u00e4ufigkeit sank bei Mastputen von 61,9 auf 45,6 Tage (\u221226\u202f%), stieg aber bei Masth\u00fchnern von 41,5 auf 45,9 Tage (+11\u202f%). Der Einsatz kritischer Antibiotika wurde in beiden Populationen stark reduziert. Bei Mastputen sanken die Resistenzraten von\n                      <jats:italic>E.\u00a0coli<\/jats:italic>\n                      signifikant, wohingegen bei Masth\u00fchnern teilweise Anstiege beobachtet wurden. Die Resistenz von\n                      <jats:italic>C.\u00a0jejuni<\/jats:italic>\n                      gegen\u00fcber Ciprofloxacin stieg trotz reduziertem Antibiotikaeinsatz. Die JIACRA-Berichte zeigen, dass die Resistenzentwicklung bei\n                      <jats:italic>E.\u00a0coli<\/jats:italic>\n                      von Tieren und Menschen mit dem Antibiotikaeinsatz in der jeweiligen Population verbunden ist, w\u00e4hrend bei\n                      <jats:italic>Campylobacter<\/jats:italic>\n                      eine direkte Beziehung zwischen tierischen und humanen Resistenzraten besteht.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Die Ergebnisse verdeutlichen die Notwendigkeit gezielter Ma\u00dfnahmen zur weiteren Reduktion des Antibiotikaeinsatzes und deuten auf komplexe Dynamiken der Resistenzentwicklung hin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00103-026-04227-5","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:12:31Z","timestamp":1775110351000},"page":"528-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Entwicklung von Antibiotikaanwendung und -resistenz in der Tierhaltung 2014\u20132024 am Beispiel von Mastputen und -h\u00fchnern sowie Auswirkungen auf den Menschen","Trends of antibiotic use and resistance in livestock from 2014 to 2024 using the example of fattening turkeys and broiler chickens as well as the effects on humans"],"prefix":"10.1007","volume":"69","author":[{"given":"Matthias","family":"Flor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd-Alois","family":"Tenhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"4227_CR1","unstructured":"Bundesministerium f\u00fcr Ern\u00e4hrung und Landwirtschaft (2019) Bericht des Bundesministeriums f\u00fcr Ern\u00e4hrung und Landwirtschaft \u00fcber die Evaluierung des Antibiotikaminimierungskonzepts der 16. AMG-Novelle. https:\/\/www.bmleh.de\/DE\/themen\/tiere\/tierarzneimittel\/kurzfassung16-amg-novelle.html. Zugegriffen: 21.01.2026"},{"key":"4227_CR2","unstructured":"Bundesinstitut f\u00fcr Risikobewertung (2026) Antibiotika-Einsatz bei Nutztieren. https:\/\/www.bfr.bund.de\/lebensmittel-und-futtermittelsicherheit\/bewertung-mikrobieller-risiken-von-lebensmitteln\/antibiotika-einsatz-bei-nutztieren\/. Zugegriffen: 26.01.2026"},{"key":"4227_CR3","unstructured":"European Medicines Agency (2026) Analysis of antimicrobial consumption and resistance (\u2019JIACRA\u2019 reports). https:\/\/www.ema.europa.eu\/en\/veterinary-regulatory-overview\/antimicrobial-resistance-veterinary-medicine\/analysis-antimicrobial-consumption-resistance-jiacra-reports. Zugegriffen: 26.01.2026"},{"key":"4227_CR4","unstructured":"16. AMG-Novelle (2013) Sechzehntes Gesetz zur \u00c4nderung des Arzneimittelgesetzes. Gesetz vom 10.10.2013 (BGBl.\u00a0I S.\u00a03813, 2014 I 272). https:\/\/www.buzer.de\/gesetz\/10963\/index.htm. Zugegriffen: 21.01.2026"},{"key":"4227_CR5","unstructured":"17. AMG-Novelle (2021) Siebzehntes Gesetz zur \u00c4nderung des Arzneimittelgesetzes. Gesetz vom 10.08.2021 (BGBl.\u00a0I S.\u00a03519, Nr.\u00a053). https:\/\/www.buzer.de\/gesetz\/14907\/index.htm. Zugegriffen: 21.01.2026"},{"key":"4227_CR6","unstructured":"TAMG (2021) Gesetz \u00fcber den Verkehr mit Tierarzneimitteln und zur Durchf\u00fchrung unionsrechtlicher Vorschriften betreffend Tierarzneimittel (Tierarzneimittelgesetz - TAMG). Gesetz vom 27.09.2021 (BGBl.\u00a0I S.\u00a04530, Nr.\u00a070). https:\/\/www.buzer.de\/TAMG.htm. Zugegriffen: 26.01.2026"},{"key":"4227_CR7","unstructured":"TAMG-Novelle (2022) Gesetz zur \u00c4nderung des Tierarzneimittelgesetzes zur Erhebung von Daten \u00fcber antibiotisch wirksame Arzneimittel und zur \u00c4nderung weiterer Vorschriften. Vorschrift vom 21.12.2022 (BGBl.\u00a0I S.\u00a02852, Nr.\u00a057). https:\/\/www.buzer.de\/gesetz\/15684\/index.htm. Zugegriffen: 20.01.2026"},{"key":"4227_CR8","unstructured":"European Medicines Agency (2019) Categorisation of antibiotics in the European Union. European Medicines Agency (EMA), Committee for Medicinal Products for Veterinary Use (CVMP), Committee for Medicinal Products for Human Use (CHMP), EMA\/CVMP\/CHMP\/682198\/2017, https:\/\/www.ema.europa.eu\/en\/documents\/report\/categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific_en.pdf. Zugegriffen: 21.01.2026"},{"key":"4227_CR9","unstructured":"Flor M, K\u00e4sbohrer A, Kaspar H, Tenhagen B\u2011A, Wallmann J (2019) Beitr\u00e4ge der Arbeitsgruppe Antibiotikaresistenz des Bundesinstituts f\u00fcr Risikobewertung (BfR) und des Bundesamtes f\u00fcr Verbraucherschutz und Lebensmittelsicherheit (BVL) zur Evaluierung der 16. AMG-Novelle. Themenkomplex\u00a01: Entwicklung der Antibiotikaabgabe- und -verbrauchsmengen sowie der Therapieh\u00e4ufigkeit. https:\/\/www.bmleh.de\/SharedDocs\/Downloads\/DE\/_Tiere\/Tiergesundheit\/Tierarzneimittel\/16-AMG-Novelle-Anlage2.pdf?__blob=publicationFile&v=2. Zugegriffen: 21.01.2026"},{"key":"4227_CR10","doi-asserted-by":"publisher","unstructured":"Flor M, K\u00e4sbohrer A, Tenhagen B\u2011A (2022) Therapieh\u00e4ufigkeit und Antibiotikaverbrauchsmengen 2018\u20132021: Entwicklung in zur Fleischerzeugung gehaltenen Rindern, Schweinen, H\u00fchnern und Puten. Bundesinstitut f\u00fcr Risikobewertung (Hrsg) Bericht vom 20.\u00a0Dezember 2022. https:\/\/doi.org\/10.17590\/20221216-083830. Zugegriffen: 21.01.2026","DOI":"10.17590\/20221216-083830"},{"key":"4227_CR11","doi-asserted-by":"publisher","unstructured":"Flor M, K\u00e4sbohrer A, Tenhagen B\u2011A (2023) Therapieh\u00e4ufigkeit und Antibiotika-Verbrauchsmengen 2022: Entwicklung in zur Fleischerzeugung gehaltenen Rindern, Schweinen, H\u00fchnern und Puten. Bundesinstitut f\u00fcr Risikobewertung (Hrsg) Wissenschaftsbericht vom 31.\u00a0August 2023. https:\/\/doi.org\/10.17590\/20230831-091916-0. Zugegriffen: 21.01.2026","DOI":"10.17590\/20230831-091916-0"},{"key":"4227_CR12","doi-asserted-by":"publisher","unstructured":"Flor M, K\u00e4sbohrer A, Tenhagen B\u2011A (2024) Antibiotika-Verbrauchsmengen und Therapieh\u00e4ufigkeit 2023: Entwicklung in Rindern, Schweinen, H\u00fchnern und Puten. Bundesinstitut f\u00fcr Risikobewertung (Hrsg) Wissenschaftsbericht des BfR vom 30.\u00a0August 2024. https:\/\/doi.org\/10.17590\/20240830-135348-0. Zugegriffen: 21.01.2026","DOI":"10.17590\/20240830-135348-0"},{"key":"4227_CR13","doi-asserted-by":"publisher","unstructured":"Flor M, Tenhagen B\u2011A (2025) Antibiotika-Verbrauchsmengen und Therapieh\u00e4ufigkeit 2024: Entwicklung in Rindern, Schweinen, H\u00fchnern und Puten. Bundesinstitut f\u00fcr Risikobewertung (Hrsg) Wissenschaftsbericht des BfR vom 28.\u00a0August 2025. https:\/\/doi.org\/10.17590\/20250825-094624-0. Zugegriffen: 21.01.2026","DOI":"10.17590\/20250825-094624-0"},{"key":"4227_CR14","unstructured":"Bundesamt f\u00fcr Verbraucherschutz und Lebensmittelsicherheit (2026) Zoonosen-Monitoring. https:\/\/www.bvl.bund.de\/DE\/Arbeitsbereiche\/01_Lebensmittel\/01_Aufgaben\/02_AmtlicheLebensmittelueberwachung\/06_ZoonosenMonitoring\/lm_zoonosen_monitoring_node.html. Zugegriffen: 26.01.2026"},{"key":"4227_CR15","unstructured":"Bundesinstitut f\u00fcr Risikobewertung (2026) ZooNotify. https:\/\/zoonotify.bfr.berlin. Zugegriffen: 16.03.2026"},{"key":"4227_CR16","doi-asserted-by":"publisher","unstructured":"European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA), European Medicines Agency (EMA) (2015) First joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals, JIACRA, 2011\u20132012. EFSA J. 13:114. https:\/\/doi.org\/10.2903\/j.efsa.2015.4006","DOI":"10.2903\/j.efsa.2015.4006"},{"key":"4227_CR17","doi-asserted-by":"publisher","unstructured":"European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA), European Medicines Agency (EMA) (2017) Second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals. JIACRA II, 2013\u20132015. EFSA J. 15:4872. https:\/\/doi.org\/10.2903\/j.efsa.2017.4872","DOI":"10.2903\/j.efsa.2017.4872"},{"key":"4227_CR18","doi-asserted-by":"publisher","unstructured":"European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA), European Medicines Agency (EMA) (2021) Third joint inter-agency report on integrated analysis of consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU\/EEA, JIACRA III, 2016\u20132018. EFSA J. 19:e06712. https:\/\/doi.org\/10.2903\/j.efsa.2021.6712","DOI":"10.2903\/j.efsa.2021.6712"},{"key":"4227_CR19","doi-asserted-by":"publisher","unstructured":"European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA), European Medicines Agency (EMA) (2024) Fourth joint inter-agency report on integrated analysis of consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU\/EEA, JIACRA IV, 2019\u20132021. EFSA J. 22:166. https:\/\/doi.org\/10.2903\/j.efsa.2024.8589","DOI":"10.2903\/j.efsa.2024.8589"},{"key":"4227_CR20","doi-asserted-by":"publisher","unstructured":"Tenhagen B\u2011A, Werner N, Kasbohrer A, Kreienbrock L (2018) Transmission pathways for resistant bacteria between animals and humans: antibiotics resistance in the One Health context. Bundesgesundheitsblatt 61:515\u2013521. https:\/\/doi.org\/10.1007\/s00103-018-2717-z","DOI":"10.1007\/s00103-018-2717-z"},{"key":"4227_CR21","doi-asserted-by":"publisher","unstructured":"Mughini-Gras L, Dorado-Garc\u00eda A, van Duijkeren E et\u00a0al. (2019) Attributable sources of community-acquired carriage of containing \u03b2\u2011lactam antibiotic resistance genes: a\u00a0population-based modelling study. Lancet Planet Health 3:E357-E369. https:\/\/doi.org\/10.1016\/S2542-5196(19)30130-5","DOI":"10.1016\/S2542-5196(19)30130-5"},{"key":"4227_CR22","doi-asserted-by":"publisher","unstructured":"Suwono B, Eckmanns T, Kaspar H et\u00a0al. (2021) Cluster analysis of resistance combinations in from different human and animal populations in Germany 2014-2017. PLoS One 16:e0244413. https:\/\/doi.org\/10.1371\/journal.pone.0244413","DOI":"10.1371\/journal.pone.0244413"},{"key":"4227_CR23","doi-asserted-by":"publisher","unstructured":"K\u00f6ck R, Brase K, Harlizius J et\u00a0al. (2013) MRSA and ESBL-producing enterobacteria in German pig holdings. Int. J. Med. Microbiol. 303:108\u2013108. https:\/\/doi.org\/10.1016\/j.ijmm.2013.08.004","DOI":"10.1016\/j.ijmm.2013.08.004"},{"key":"4227_CR24","doi-asserted-by":"publisher","unstructured":"Bisdorff B, Scholh\u00f6lter JL, Claussen K, Pulz M, Nowak D, Radon K (2012) MRSA-ST398 in livestock farmers and neighbouring residents in a\u00a0rural area in Germany. Epidemiology and Infection 140:1800\u20131808. https:\/\/doi.org\/10.1017\/S0950268811002378","DOI":"10.1017\/S0950268811002378"},{"key":"4227_CR25","doi-asserted-by":"publisher","unstructured":"Mulders MN, Haenen APJ, Geenen PL et\u00a0al. (2010) Prevalence of livestock-associated MRSA in broiler flocks and risk factors for slaughterhouse personnel in The Netherlands. Epidemiol. Infect. 138:743\u2013755. https:\/\/doi.org\/10.1017\/S0950268810000075","DOI":"10.1017\/S0950268810000075"},{"key":"4227_CR26","doi-asserted-by":"publisher","unstructured":"van Cleef BAGL, Broens EM, Voss A et\u00a0al. (2010) High prevalence of nasal MRSA carriage in slaughterhouse workers in contact with live pigs in The Netherlands. Epidemiol. Infect. 138:756\u2013763. https:\/\/doi.org\/10.1017\/S0950268810000245","DOI":"10.1017\/S0950268810000245"},{"key":"4227_CR27","doi-asserted-by":"publisher","unstructured":"Dorado-Garcia A, Mevius DJ, Jacobs JJ et\u00a0al. (2016) Quantitative assessment of antimicrobial resistance in livestock during the course of a\u00a0nationwide antimicrobial use reduction in the Netherlands. J. Antimicrob. Chemother. 71:3607\u20133619. https:\/\/doi.org\/10.1093\/jac\/dkw308","DOI":"10.1093\/jac\/dkw308"},{"key":"4227_CR28","doi-asserted-by":"publisher","unstructured":"Rosner BM, Schielke A, Didelot X et\u00a0al. (2017) A combined case-control and molecular source attribution study of human infections in Germany, 2011\u20132014. Sci. Rep. 7:5139. https:\/\/doi.org\/10.1038\/s41598-017-05227-x","DOI":"10.1038\/s41598-017-05227-x"},{"key":"4227_CR29","doi-asserted-by":"publisher","unstructured":"Pascoe B, Futcher G, Pensar J et\u00a0al. (2024) Machine learning to attribute the source of infections in the United States: A\u00a0retrospective analysis of national surveillance data. J. Infect. 89:106265. https:\/\/doi.org\/10.1016\/j.jinf.2024.106265","DOI":"10.1016\/j.jinf.2024.106265"},{"key":"4227_CR30","unstructured":"Siller P, Klabunde-Negatsch A, Sander S, Heberer T (2024) Abgabemengenerfassung von Antibiotika in Deutschland 2023. Deutsches Tier\u00e4rzteblatt 72:1554\u20131567."},{"key":"4227_CR31","doi-asserted-by":"publisher","unstructured":"Perrin-Guyomard A, Hou\u00e9e P, Lucas P et\u00a0al. (2023) Prevalence and molecular epidemiology of mcr-mediated colistin-resistance Escherichia coli from healthy poultry in France after national plan to reduce exposure to colistin in farm. Front. Microbiol. 14:1254122. https:\/\/doi.org\/10.3389\/fmicb.2023.1254122","DOI":"10.3389\/fmicb.2023.1254122"},{"key":"4227_CR32","doi-asserted-by":"publisher","unstructured":"Luo ND, Pereira S, Sahin O et\u00a0al. (2005) Enhanced fitness of fluoroquinolone-resistant in the absence of antibiotic selection pressure. Proc. Natl. Acad. Sci. U. S. A. 102:541\u2013546. https:\/\/doi.org\/10.1073\/pnas.0408966102.","DOI":"10.1073\/pnas.0408966102"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-026-04227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-026-04227-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-026-04227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:29:53Z","timestamp":1777577393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-026-04227-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4227"],"URL":"https:\/\/doi.org\/10.1007\/s00103-026-04227-5","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Flor und B.-A.\u00a0Tenhagen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}